UBM — Ulisse Biomed Spa Income Statement
0.000.00%
- €20.20m
- €20.14m
- €0.77m
- 23
- 18
- 60
- 21
Annual income statement for Ulisse Biomed Spa, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.429 | 0.277 | 0.138 | 0.066 | 0.768 |
| Cost of Revenue | |||||
| Gross Profit | 0.2 | -0.269 | -0.895 | -1.55 | -1.08 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.204 | 0.88 | 1.44 | 4.86 | 6.68 |
| Operating Profit | 0.224 | -0.603 | -1.31 | -4.8 | -5.91 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 0.224 | -0.604 | -1.31 | -4.8 | -5.94 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 0.222 | -0.604 | -1.31 | -4.8 | -5.94 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 0.222 | -0.604 | -1.31 | -4.8 | -5.94 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 0.222 | -0.604 | -1.31 | -4.8 | -5.94 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.028 | -0.075 | -0.162 | -0.578 | -0.148 |